Skip to content

Complications associated with two power-injectable Peripherally Inserted Central Catheters (PICCs).

Adverse events and costs associated with two power-injectable Peripherally Inserted Central Catheters (PICCs) at an adult hospital: A randomised controlled trial.

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000930886
Enrollment
304
Registered
2012-08-31
Start date
2013-01-14
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The proposed study will evaluate the safety and costs associated with use of two PICC designs. The primary aim is to ascertain whether a new anti-thrombotic design is associated with less adverse events and need for removal than third-generation polyurethane. Additionally costs associated with using this new technology will be evaluated.

Interventions

Adult patients who are already assigned to receive a PICC as part of their standard medical care will be randomly allocated to receive either an anti-thrombotic or a third-generation polyurethane proximal valve, power-injectable PICC. Both PICCs will be inserted using the same method (modified-Seldinger technique) by specially trained registered nurses in the Radiology department. The duration of the procedure varies according to the vasculature of the patient but approximately takes 30 minutes.

Adult patients who are already assigned to receive a PICC as part of their standard medical care will be randomly allocated to receive either an anti-thrombotic or a third-generation polyurethane proximal valve, power-injectable PICC. Both PICCs will be inserted using the same method (modified-Seldinger technique) by specially trained registered nurses in the Radiology department. The duration of the procedure varies according to the vasculature of the patient but approximately takes 30 minutes. Both PICCs have power-injectable capability and incorporate proximal valves, they differ in regards to the materials they are manufactured from; one is a third generation polyurethane and the other contains an anti-thrombotic polymer. The PICC will stay in situ until treatment is completed or as decided by the treating team.

Sponsors

Ms. Rebecca Sharp
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- All adult (18 years or older) patients who are to have a PICC inserted above the ante-cubital fossa region (as per normal practice) by one of the two lead nurse PICC inserters in the Radiology Department at the proposed study site. - Agree to and are able to be followed up by telephone

Exclusion criteria

- Inability to provide informed consent due to neurological barriers (diagnosis of dementia; uncontrolled mental illness or cognitive deficits) - Unable to read, write or understand English - Have already been included in the trial

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026